Armata Pharmaceuticals (ARMP) Non-Current Deffered Revenue (2018)

Armata Pharmaceuticals (ARMP) reported Non-Current Deffered Revenue of $810000.0 for Q4 2018.

Armata Pharmaceuticals (ARMP) Non-Current Deffered Revenue (2018) Analysis & Trends

Armata Pharmaceuticals (ARMP) has 1 years of Non-Current Deffered Revenue data on file, last reported at $810000.0 in Q4 2018.

For the quarter ending Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $810000.0; the trailing twelve-month figure through Dec 2018 stood at $810000.0 (changed N/A YoY), and the FY2018 full-year result was $810000.0, changed N/A from the prior year.
Non-Current Deffered Revenue held at $810000.0 in Q4 2018.
In the past five years, Non-Current Deffered Revenue ranged from a high of $810000.0 in Q4 2018 to a low of $810000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Armata Pharmaceuticals	191.29 Mn	186.49 Mn	-	-

Download Data

Date	Value
Dec 31, 2018	810,000.00